- en: <!--yml
  id: totrans-split-0
  prefs: []
  type: TYPE_NORMAL
- en: 'category: 未分类'
  id: totrans-split-1
  prefs: []
  type: TYPE_NORMAL
- en: 'date: 2024-05-27 14:49:58'
  id: totrans-split-2
  prefs: []
  type: TYPE_NORMAL
- en: -->
  id: totrans-split-3
  prefs: []
  type: TYPE_NORMAL
- en: 'FDA Approves Wegovy For Heart Conditions in Game-Changing Move : ScienceAlert'
  id: totrans-split-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
- en: 来源：[https://www.sciencealert.com/fda-approves-wegovy-for-heart-conditions-in-game-changing-move](https://www.sciencealert.com/fda-approves-wegovy-for-heart-conditions-in-game-changing-move)
  id: totrans-split-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: The US Food and Drug Administration has given the green light for a popular
    anti-obesity drug to be used to prevent serious heart conditions for the first
    time, in a move likely to expand insurance coverage.
  id: totrans-split-6
  prefs: []
  type: TYPE_NORMAL
- en: Wegovy, produced by Danish pharmaceutical giant Novo Nordisk, was approved "to
    reduce the risk of cardiovascular death, heart attack and stroke in adults with
    cardiovascular disease and either obesity or overweight," the FDA said in a [statement](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or).
  id: totrans-split-7
  prefs: []
  type: TYPE_NORMAL
- en: The FDA's decision could be a game changer for the approximately 70 percent
    of American adults who it says are either obese or overweight, by potentially
    expanding the pool of people eligible to have their insurance cover these expensive
    but effective injected medicines.
  id: totrans-split-8
  prefs: []
  type: TYPE_NORMAL
- en: '"This patient population has a higher risk of cardiovascular death, heart attack
    and stroke," John Sharretts, the director of the FDA''s Division of [Diabetes](https://www.sciencealert.com/diabetes),
    Lipid Disorders and Obesity, said in a statement.'
  id: totrans-split-9
  prefs: []
  type: TYPE_NORMAL
- en: '"Providing a treatment option that is proven to lower this cardiovascular risk
    is a major advance for public health," he added.'
  id: totrans-split-10
  prefs: []
  type: TYPE_NORMAL
- en: Approval was based on a multinational trial involving 17,500 patients, with
    about half assigned the drug and the other half given a [placebo](https://www.sciencealert.com/what-is-a-placebo).
    Both groups received standard medical care for the management of blood pressure
    and cholesterol, and both received healthy lifestyle counselling on diet and exercise.
  id: totrans-split-11
  prefs: []
  type: TYPE_NORMAL
- en: 'The group that received Wegovy were 20 percent less likely to experience major
    cardiac events: death from cardiovascular causes, non-fatal heart attacks and
    non-fatal strokes.'
  id: totrans-split-12
  prefs: []
  type: TYPE_NORMAL
- en: While Wegovy has been approved since 2021 to treat obesity, many insurers do
    not cover it. Obesity Action Coalition, a patient advocacy organization, said
    they hoped the expansion of its use would remedy the situation.
  id: totrans-split-13
  prefs: []
  type: TYPE_NORMAL
- en: Insurers "should have been providing coverage for anti-obesity medications prior
    to the announcement. Now, there should be no doubt that this treatment must be
    covered. Lives are at stake," the group said.
  id: totrans-split-14
  prefs: []
  type: TYPE_NORMAL
- en: The recent surge in popularity of anti-obesity drugs including Wegovy and Ozempic,
    which mimic a gut hormone to suppress appetite, has padded the profits of the
    companies that make them.
  id: totrans-split-15
  prefs: []
  type: TYPE_NORMAL
- en: In fact, Novo Nordisk, which produces both Wegovy and Ozempic, has been so profitable
    that it has helped to keep the Danish economy afloat, according to Danske Bank.
  id: totrans-split-16
  prefs: []
  type: TYPE_NORMAL
- en: The pharmaceutical giant's success "is pushing overall activity levels up, while
    much of the rest of industry and housing construction have contracted," Heidi
    Schauman, the bank's global head of research, wrote in a note earlier this week.
  id: totrans-split-17
  prefs: []
  type: TYPE_NORMAL
- en: Novo Nordisk's head of development, Martin Holst Lange, welcomed the FDA's announcement,
    calling it "an important milestone for people living with obesity and cardiovascular
    disease."
  id: totrans-split-18
  prefs: []
  type: TYPE_NORMAL
- en: Wegovy "has the potential to prolong lives by addressing some of the leading
    causes of preventable deaths by reducing the risks of cardiovascular events,"
    he said in a statement.
  id: totrans-split-19
  prefs: []
  type: TYPE_NORMAL
- en: '*© [Agence France-Presse](terms-and-conditions)*'
  id: totrans-split-20
  prefs: []
  type: TYPE_NORMAL
